


CURRENT RESEARCH TOPICS IN PHARMACY:

An Overview of Novelties in Cancer Treatment

February 15th, 2024



FIRST SESSION

10:00-11:30 AM

Moderator:

*Betül
OKUYAN*

Welcome

Prof.Hatice Kübra ELÇİOĞLU

*Natural products mediated targeting
of deregulated signaling pathways for
chemoprevention of carcinogenesis
and metastasis*

Prof. Ahmed Ammad Farooqi

Mesoporous silica nanoparticles: A
smart tool for biomedical applications
Assoc.Prof.Fahima Dilnawaz

Phytosomes: A Dynamic Innovation in
Cancer Treatment
Assist. Prof. Dhanashree Sanap

SECOND SESSION

13:00-14:30 PM

Moderator:

*Ceyda EKENTOK
ATICI*

Increased awareness of sex and
gender as modulators of cancer risk
and outcome is required among
cancer researchers

Assoc.Prof.Berna Özdemir

*Management of oral chemotherapy-
related problems in cancer patients*
Pharmacist Elif Aras Atik

Cervical Cancer Treatment and HPV
Vaccination: Preventive Priority for
Future Generations

Assist. Prof. Sneha Agrawal

THIRD SESSION

15:30-17:00 PM

Moderator:

Esra TATAR

Exploring new drug delivery avenues
for targeted and localized cancer
therapy through advanced
nanotherapeutics
Assist.Prof.Monika Dwivedi

Plectranthus: A Valuable Source of
Bioactive Compounds for Therapeutic
Applications

Assoc.Prof.Patricia Rijo

Targeted delivery of ligand-displaying
exosomes using RNA
nanotechnology for breast cancer
Dr.Burcu Üner

CHAIR

Prof. Hatice Kübra ELÇİOĞLU

VICE CHAIRS

Prof. Levent KABASAKAL & Assoc. Prof. Esra TATAR & Dr.Ayşe Nur HAZAR YAVUZ

ORGANIZING & SCIENTIFIC COMMITTEE

Editorial Board of Journal of Research in Pharmacy

<https://www.jrespharm.com/>

JRP

Journal of Research in Pharmacy

An international open-access journal of pharmacy and pharmaceutical sciences
Formerly published as Marmara Pharmaceutical Journal

**ONLINE
SYMPOSIUM**

CURRENT RESEARCH TOPICS IN PHARMACY:

An Overview of Novelties in Cancer Treatment

February 15th, 2024

ORGANIZING & SCIENTIFIC COMMITTEE
Editorial Board of Journal of Research in Pharmacy
<https://www.jrespharm.com/>

Esra Tatar
(Vice Chair of Organizing Committee)
Marmara University, Istanbul, Türkiye

Levent Kabasakal
(Vice Chair of Organizing Committee)
Marmara University, Istanbul, Türkiye

Ayşe Nur Hazar Yavuz
(Vice Chair of Organizing Committee)
Marmara University, Istanbul, Türkiye

Abdihartim Mohammed Abdi
Yeditepe University, Istanbul, Türkiye

Afife Böyü Uğur Kaplan
Atatürk University, Erzurum, Türkiye

Ahmed Hamza Al-Shammari
Kut University College, Wasit, Iraq

Ahmet Emir
Ege University, Izmir, Türkiye

Ali Demir Sezer
Marmara University, Istanbul, Türkiye

Ammad Ahmad Farooqi
Institute of Biomedical and Genetic Engineering (IBGE), Islamabad, Pakistan

Ana V. Pejić
University of Kragujevac, Kragujevac, Serbia

Anil Kumar Dwivedi
Central Drug Research Institute, Lucknow, India

Anisa Elhami
University of Tripoli, Tripoli, Libya

Annalisa Chiveroli
G. d'Annunzio University of Chieti-Pescara, Chieti, Italy

Anjoaneta Trendafilova
Bulgarian Academy of Sciences, Sofia, Bulgaria

Ayşe Toprak Semic
Giresun University, Giresun, Türkiye

Ayfer Beceren
Marmara University, Istanbul, Türkiye

Ayşe Esra Karadağ
Istanbul Medipol University, Istanbul, Türkiye

Aygenur Günaydin Akyıldız
Bezmialem Vakıf University, Istanbul, Türkiye

Bahadır Bülbül
Düzce University, Düzce, Türkiye

Berna Doğan
Istanbul Technical University, Istanbul, Türkiye

Betül Okuyan
Marmara University, Istanbul, Türkiye

Beysa Ecem Öz Bedir
Ankara Yıldırım Beyazıt University, Ankara, Türkiye

Birca Öner
The University of Health Science and Pharmacy in St. Louis, USA

Bilge Eray
Marmara University, Istanbul, Türkiye

Ceren Emir
Ege University, Izmir, Türkiye

Ceyda Ekenok Altıncı
Marmara University, Istanbul, Türkiye

Claudio Ferrante
G. d'Annunzio University of Chieti-Pescara, Chieti, Italy

Debora Dummer Meira
Federal University of Espírito Santo, Vitória- Espírito Santo, Brazil

Derya Özazvici
Marmara University, Istanbul, Türkiye

Dhanashree P. Sanap
Bharati Vidyapeeth's College of Pharmacy, Navi Mumbai, India

Dinesh Kumar
Indian Institute of Technology (BHU), Varanasi, India

Ebru Allıntaş
Istanbul University, Istanbul, Türkiye

Efe Doğanhan Dincel
Istanbul University, Istanbul, Türkiye

Ela Hölü
University of Medicine, Tirana, Albania

Emine Terzi
Ankara Yıldırım Beyazıt University, Ankara, Türkiye

Emirhan Nemli
Hacettepe University, Ankara, Türkiye

Emre Kara
Hacettepe University, Ankara, Türkiye

Emrah Özakar
Atatürk University, Erzurum, Türkiye

Enkelajo Gosti
Aldent University, Tirana, Albania

Eniola Habeti
University of Medicine, Tirana, Albania

Ercan Rayman
Marmara University, Istanbul, Türkiye

Ermelinda Dumishi
Ministry of Education and Sports, Tirana, Albania

Fatma Misoune
University of Mostaganem, Mostaganem, Algeria

Gizem Tatar Yılmaz
Karadeniz Technical University, Trabzon, Türkiye

Gülberk Uğur
Hacettepe University, Ankara, Türkiye

Gülşah Tınaz
Marmara University, Istanbul, Türkiye

Gülşah Gedik
Trakya University, Edirne, Türkiye

Heider A. Abdulsamer
Al-Maadiq University, Basra, Iraq

Hamide Sena Özbay
Hacettepe University, Ankara, Türkiye

Hasan Erding Sallıtepe
Karadeniz Technical University, Trabzon, Türkiye

İgıl Yıldırım
Beykent University, Istanbul, Türkiye

İ İrem Tali Çankaya
Hacettepe University, Ankara, Türkiye

Kerem Buran
University of Health Sciences, Istanbul, Türkiye

Kiava Stjepi
Albanian University, Tirana, Albania

Khododa Dhamo
Aldent University, Tirana, Albania

Laleh Khodaei
Tabriz University of Medical Sciences, Tabriz, Iran

Lejla Kikoo
University of Sarajevo, Sarajevo, Bosnia and Herzegovina

Lokman Aray
Trakya University, Edirne, Türkiye

Long Chiau Ming
Sunway University, Sunway City, Malaysia

Lorana Memushaj
Aldent University, Tirana, Albania

Lynda Bourebaba
Wroclaw University of Environmental and Life Sciences, Wroclaw, Poland

Maja Orner Hadzibabic
University of Zagreb, Zagreb, Croatia

Mehmet Gümüştaş
Ankara University, Ankara, Türkiye

Mehmet Özül
Gebze Technical University, Kocaeli, Türkiye

Merve Kabasakal
University of Health Sciences, Istanbul, Türkiye

Mesut Sancar
Marmara University, Istanbul, Türkiye

Milod N. Milosavljević
University of Kragujevac, Kragujevac, Serbia

Mirela Miraj
University of Medicine, Tirana, Albania

Mirjana Marčević
University of Belgrade, Belgrade, Serbia

Mohammed Jabbar Manna
Al-Mustansirya University, Baghdad, Iraq

Mohd Younis Rather
Government Medical College Srinagar, Srinagar, India

Murat Doğan
Cumhuriyet University, Sivas, Türkiye

Nasir İskidek
Petra University, Amman, Jordan

Nurdan Tekin
University of Health Sciences, Istanbul, Türkiye

Nurettin Yaylı
Karadeniz Technical University, Trabzon, Türkiye

Oğun Mehmet Saka
Ankara University, Ankara, Türkiye

Onur Serçinoğlu
Gebze Technical University, Kocaeli, Türkiye

Oya Kermiçli
Marmara University, Istanbul, Türkiye

Pablo Miralles Ibarra
University of Valencia, Burjassot, Spain

Pankaj Dwivedi
The University of Health Science and Pharmacy in St. Louis, USA

Patricia Rijo
Lusofona University, Lisbon, Portugal

Pinar Talay Pinar
Yüzüncü Yıl University, Van, Türkiye

Rajankant Patel
Granules Pharmaceuticals Inc., Chantilly, VA - 20151, USA

Renuka Khalik
Washington University in St. Louis, USA

Rezzarta Shkrelli
Aldent University, Tirana, Albania

Rukiye Sevinç Özakar
Atatürk University, Erzurum, Türkiye

Rümeysa Keleş Kaya
Sakarya University, Sakarya, Türkiye

Saeidh Soltani
Isfahan University of Medical Sciences, Isfahan, Iran

Sahar Al-Dokki
National Research Centre, Cairo, Egypt

Sakine Tunçay Tamer
Ege University, Izmir, Türkiye

Sana Rehman
HIMSR & HAHC Hospital, Jamia Hamdard, New Delhi, India

Selma Houchi
University Ferhat Abbas, Setif, Algeria

Shahram Khademvatan
Urmia University of Medical Sciences, Urmia, Iran

Simone Carradori
G. d'Annunzio University of Chieti-Pescara, Chieti, Italy

Sihan Sermet
Istanbul Arel University, Istanbul, Türkiye

Sinem Göktürk
Marmara University, Istanbul, Türkiye

Sneha Agrawal
Bharati Vidyapeeth's College of Pharmacy, Navi Mumbai, Maharashtra, India

Somaiah Soltani
Tabriz University of Medical Sciences, Tabriz, Iran

Tarık Çatlı
Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina

Turgut Taşkın
Marmara University, Istanbul, Türkiye

Uğur Kırarçöz
Trakya University, Edirne, Türkiye

Onur Yaman
Kilip Çelebi University, Izmir, Türkiye

Youssefvan Mani
Qassim University, Al Qassim, Kingdom of Saudi Arabia

Viktorija Maksimova
Goce Delchev University, Sht. Republic of N. Macedonia

Vladan Çelikkoy
Cardiff University, Cardiff, UK

Vilma Toska Papajani
University of Medicine, Tirana, Albania

Zahraa Amer Hashim
Mosul University, Mosul, Iraq

Zeynep Nigar Özdemir Kumral
Marmara University, Istanbul, Türkiye

Zeyna Alhanoum
Mosul University, Mosul, Iraq

Zoran Zeković
University of Novi Sad, Novi Sad, Serbia

JRP

Journal of Research in Pharmacy

An international open-access journal of pharmacy and pharmaceutical sciences
Formerly published as Marmara Pharmaceutical Journal

ONLINE
SYMPOSIUM

MANAGEMENT of ORAL CHEMOTHERAPY-RELATED PROBLEMS

Elif ARAS ATIK^{ID}*

Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara,
Türkiye.

eczelifaras@gmail.com

*Corresponding and presenting author

Advances in cancer treatment have led to new treatment options. Since 1953, oral chemotherapy has been used. The first oral chemotherapy agents were mercaptopurine and methotrexate, followed by capecitabine in 1998. In the early 2000s, approximately 5% of the treatments used were oral chemotherapy, in 2007 this rate was 17%. This rate is expected to reach approximately 30% soon. In the treatment of breast cancer, colorectal cancer, lung cancer, lymphoma, leukemia, multiple myeloma, kidney and prostate cancers, targeted drugs, hormonal chemotherapy, and conventional chemotherapy are frequently used alone or in combination.

When the mechanisms of oral chemotherapy drugs are examined, it is known that they act through 3 basic mechanisms: surface proteins, tumor biological pathways and receptor-targeted small molecule inhibitors. Capecitabine, busulfan and melphalan, among the conventional chemotherapy drugs, can be shown among the drugs frequently used orally in the clinic. Gefitinib, imatinib, erlotinib and sunitinib was among the first oral agents to be used as a targeted agent.

Since patients using oral chemotherapy take their medication at home. The frequency of doctor's visits sometimes varies according to the re-prescription of the medication, the patient has less under the supervision of health professionals than the patient using intravenous medication, and this leads to the patient having an important role in the management of his/her treatment. Among the advantages of oral chemotherapy; are being comfortable and easy to apply, taking the drug at home, the patient's self-management, lack of problems related to the use of venous catheter, low toxic effect, effect on quality of life, cost-reducing aspect, increased participation in daily and social activities, and reduction of personnel allocation for the patient receiving inpatient treatment in the clinic.

Toxic effects due to wrong and inappropriate drug use, failure to ensure safety in antineoplastic drug administration by the patient and his family (exposure to waste), food interactions (inability to adjust the usage interval of the drug) and drug interactions (increase in polypharmacy drug use due to other accompanying diseases) are among the disadvantages of oral chemotherapy.

Access to medicine, compliance problems, polypharmacy, drug interactions, nutrient interactions, safe drug use and adverse effect problems are among the common problems encountered in the use of oral chemotherapy.

Strategies that can be applied to properly manage the problems that arise during the use of oral chemotherapy include: treatment dosage schedules should be given to all patients clearly and understandably, they should be taught what to do in case of missing a dose or vomiting, they should be educated about heat, light and storage conditions, all prescription and non-prescription medications, vitamins, supplements and alternative treatment products should be checked by the pharmacist for interactions.

Keywords: Cancer; oral chemotherapy; problems; management.

References

- [1] Segal EM, Flood MR, Mancini RS, Whiteman RT, Friedt GA, Kramer AR, Hofstetter MA. Oral chemotherapy food and drug interactions: a comprehensive review of the literature. *J Oncol Pract.* 2014;10(4):e255-268. <https://doi.org/10.1200/jop.2013.001183>.
- [2] Mancini R, Wilson D. A Pharmacist-Managed Oral Chemotherapy Program. *Oncol Issues.* 2012; 27(1): 28-31. <https://doi.org/10.1080/10463356.2012.11883635>.
- [3] Goodin S, Griffith N, Chen B, Chuk K, Daouphars M, Doreau C, Patel RA, Schwartz R, Tamés MJ, Terkola R, Vadnais B, Wright D, Meier K. Safe handling of oral chemotherapeutic agents in clinical practice: recommendations from an international pharmacy panel. *J Oncol Pract.* 2011;7(1):7-12. <https://doi.org/10.1200/jop.2010.000068>.